News

not found

Working nights leads to a higher chance of memory loss, experts warn

People on the night shift may run a greater risk of memory loss compared to those takin’ care of business during the day, a new study has shown. Researchers at York University in Canada found that those working shifts outside the average 9 a.m. to 5 p.m. schedule were more prone to suffer from cognitive impairments, such as inability to think clearly, brain deterioration and behavioral changes. The study, which gathered data on 47,811 adults and analyzed self-reported employment information alongside the results of cognitive function tests, was published this week in the open-access journal PLOS ONE. “Findings suggest a potential link between shift work exposure and cognitive function impairment,” the experts concluded. Working nights could lead to memory loss in middle-aged and older adults as those working late have 79% higher rates of cognitive impairment. And while the overnighters may have been more likely to suffer from issues with memory, those on more regular hours were more likely to struggle with the ability to manage their own thoughts, emotions and actions. Nearly one in five individuals (21%) are likely to engage in shift work during their careers. The experts suggest that the disruption to a person’s circadian rhythm caused by shift work is likely causing these detrimental impacts to people’s cognitive function, especially in middle-aged and older adults. Every cell in the body operates on a circadian clock, an internally driven 24-hour rhythm that often runs longer than 24 hours. It resets every day by the sun’s cycle but can be disrupted by too much or too little sunlight exposure — a common issue for shift workers. A person’s circadian clock sets the timing for many important bodily functions including sleep cycles, hormonal activity, body temperature rhythm, eating and digesting.  Every adult should be tucking themselves in for at least seven hours a night, according to the Centers for Disease Control and Prevention. It’s estimated that nearly half of Americans are sleep-deprived. Offsetting the body’s circadian rhythm has been associated with a higher risk of a multitude of health issues including chronic diseases, depression, obesity, Type 2 diabetes, cardiovascular problems and headache disorders.

  • 29 August, 19:53
  • Read more
not found

The Global Pharmaceutical Leaders’ Club invites you for the 4th Eurasian Pharmaceutical Summit, which will be held with the support of the Pharmaceutical Industry Development Agency of the Ministry of Investment

The Global Pharmaceutical Leaders’ Club invites you for the 4th Eurasian Pharmaceutical Summit, which will be held with the support of the Pharmaceutical Industry Development Agency of the Ministry of Investment, Industry and Trade of the Republic of Uzbekistan. The summit will be held in a hybrid format on the 26th - 28th September with an offline part in Samarkand. This is the only conference that comprehensively covers the development trends in the pharmaceutical markets of the countries in Central Asia, the Caucasus and Eastern Europe. In an offline format the summit will bring together 250+ leading pharmaceutical market professionals from 10 countries and 100+ speakers from regulatory authorities, pharmaceutical manufacturing companies, distributors and pharmacy chains. The summit programme includes 20+ sessions, where the issues of market access, registration of pharmaceutical drugs, public procurement, labelling, pricing, sales, marketing and production of medicines will be discussed. There will be round tables with regulators and one-to-one meetings with top managers of leading pharmaceutical companies. For the first time, within the framework of the summit, visits to pharmaceutical drug distribution centres and manufacturing enterprises in Samarkand will be organised. As a part of the Eurasian Pharmaceutical Summit, the Eurasian Pharma Awards competition will be held for the 4th time. International and local pharmaceutical drug manufacturers, distributors and pharmacy chains are invited to participate. Details about the summit are on the website: https://eurasianpharmasummit.com/en/. 

  • 16 August, 08:56
  • Read more
not found

Drug prices reach new high — in the millions

A new era of expensive drugs has arrived: medicines priced in the millions of dollars a patient. U.S. or European health regulators have approved four new products intended as one-time treatments for rare genetic diseases that carry list prices of at least $2 million a patient. The most recent one approved in the U.S. set a price record: $3.5 million for CSL Ltd.’s Hemgenix, a treatment for the blood disorder hemophilia B. The price tags mark a new high for medicines, which drugmakers were once reluctant to charge more than six figures for but whose prices have been heading upward. The companies say the cost reflects the drugs’ potential to help patients in a single dose, but paying for it could challenge patients and health insurers. Most of the multimillion-dollar treatments are gene therapies, a groundbreaking type of treatment that involves injecting a functional gene into a person to correct a faulty, disease-causing one. Bluebird’s Skysona gene therapy for a rare neurological disease affecting children costs $3 million, while its Zynteglo for an inherited blood disorder is priced at $2.8 million. Novartis AG’s Zolgensma gene therapy treating a muscle-wasting condition costs $2.1 million. Some of the new therapies could produce long-term savings, the companies say,by sparing patients from having to take older treatments repeatedly for the rest of their lives. McKinsey & Co. estimates that about 30 new gene therapies could be introduced in 2024 alone.

  • 15 August, 09:02
  • Read more
Нажмите на кнопку ниже, чтобы прослушать текст Powered by GSpeech